ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ANI Pharmaceuticals, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Net Sales has grown by an annual rate of 30.49%
3
With a growth in Operating Profit of 7.93%, the company declared Outstanding results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 139.13 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 2.85 times
- DEBTORS TURNOVER RATIO(HY) Highest at 3.82 times
4
With ROCE of 0.14%, it has a risky valuation with a 2.02 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 41.92%, its profits have fallen by -148.5%
5
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to ANI Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ANI Pharmaceuticals, Inc. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
ANI Pharmaceuticals, Inc.
45.49%
0.74
37.94%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
30.49%
EBIT Growth (5y)
21.65%
EBIT to Interest (avg)
-0.55
Debt to EBITDA (avg)
36.46
Net Debt to Equity (avg)
1.18
Sales to Capital Employed (avg)
0.62
Tax Ratio
23.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.20%
ROE (avg)
1.25%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.22
EV to EBIT
1454.34
EV to EBITDA
23.83
EV to Capital Employed
2.02
EV to Sales
2.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.14%
ROE (Latest)
-3.27%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend28What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 139.13 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 2.85 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.82 times
NET SALES(Q)
Highest at USD 211.37 MM
RAW MATERIAL COST(Y)
Fallen by -13.17% (YoY
OPERATING PROFIT(Q)
Highest at USD 38.45 MM
PRE-TAX PROFIT(Q)
Highest at USD 11.47 MM
NET PROFIT(Q)
Highest at USD 8.5 MM
-6What is not working for the Company
INTEREST(HY)
At USD 16.33 MM has Grown at 76.42%
Here's what is working for ANI Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 11.47 MM has Grown at 318.23%
over average net sales of the previous four periods of USD -5.26 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 8.5 MM has Grown at 348.66%
over average net sales of the previous four periods of USD -3.42 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 139.13 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 211.37 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 2.85 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.82 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
At USD 211.37 MM has Grown at 25.43%
over average net sales of the previous four periods of USD 168.52 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 38.45 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 11.47 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 8.5 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -13.17% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 23.28 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for ANI Pharmaceuticals, Inc.
Interest
At USD 16.33 MM has Grown at 76.42%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
